Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRACT: Almonertinib + Bevacizumab in EGFR-Mutant NSCLC with Leptomeningeal Metastasis
NCT04944069Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jul 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Overall Survival up to 2 years. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT04944069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944069.